Table 1.
(a): Baseline characteristics of patients treated with 223Ra tabulated according to NLR. All values are median (IQR) or frequencies (%). (b): Baseline characteristics of patients treated with Docetaxel tabulated according to NLR. All values are median (IQR) or frequencies (%).
| (a) | ||||
|
Whole Sample
(n = 149) (%) |
NLR Low (
≤
5)
(n = 105) (%) |
NLR High (>5)
(n = 23) (%) |
p -Value | |
| Prior Docetaxel treatment | 0.21 | |||
| No | 65 (43.6%) | 42 (40%) | 6 (26.1%) | |
| Yes | 84 (56.4%) | 63 (60%) | 17 (73.9%) | |
| Age (years) | 72 (65; 79) | 71 (64; 77) | 74 (66; 79.5) | 0.83 |
| Missing | 1 | 1 | 0 | |
| ECOG | 0.04 | |||
| 0 | 50 (36.8%) | 42 (43.8%) | 4 (17.4%) | |
| 1 | 68 (50%) | 45 (46.9%) | 15 (65.2%) | |
| 2 | 18 (13.2%) | 9 (9.4%) | 4 (17.4%) | |
| Missing | 13 | 9 | 0 | |
| PSA levels (ng/mL) | 53.2 (14.8; 182) | 38.3 (10.1; 122.5) | 86.2 (23.8; 307.6) | 0.79 |
| Missing | 7 | 1 | 0 | |
| tALP (IU/L) | 106 (69.5; 198.5) | 96 (67; 156) | 86.2 (23.8; 307.6) | 0.1 |
| Missing | 18 | 6 | 0 | |
| Hb (g/L) | 122 (113.8; 133) | 96 (67; 156) | 158 (92; 267) | 0.07 |
| Missing | 9 | 0 | 0 | |
| White blood count (109/L) | 6.5 (5.3; 7.9) | 6.2 (5.2; 7.9) | 7.7 (6.8; 9) | 0.01 |
| Neutrophils (109/L) | 4.4 (3.5; 5.6) | 4.1 (3.3; 5.1) | 5.7 (5.3; 6.6) | 0.001 |
| Lymphocytes (109/L) | 3.5 (2.5; 4.6) | 1.4 (1.1; 1.9) | 1 (0.7; 1.1) | <0.001 |
| NLR | 3.5 (2.5; 4.6) | 3.2 (2.3; 4) | 5.8 (5.4; 7) | |
| Missing | 21 | 0 | 0 | |
| Platelets (109/L) | 239 (186.8; 287) | 237 (186; 285) | 246 (209; 322) | 0.16 |
| Missing | 9 | 0 | 0 | |
| (b) | ||||
|
Whole Sample
(n = 170) (%) |
NLR Low (
≤
5)
(n = 76) (%) |
NLR High (>5)
(n = 16) (%) |
p -Value | |
| Age | 67 (59; 74) | 69 (59.5; 75.5) | 66.5 (59.8; 69.2) | 0.15 |
| Missing | 1 | 1 | 0 | |
| Cancer Type | ||||
| Hormone-sensitive | 20 (12%) | 14 (18.7%) | 3 (18.8%) | 1 |
| Castration resistant | 147 (88%) | 61 (81.3%) | 13 (81.2%) | |
| Missing | 3 | 1 | 0 | |
| ECOG | 0.25 | |||
| 0 | 55 (43.7%) | 25 (58.1%) | 4 (36.4%) | |
| 1 | 57 (45.2%) | 12 (27.9%) | 6 (54.5%) | |
| 2 | 14 (11.1%) | 12 (27.9%) | 1 (9.1%) | |
| Missing | 44 | 33 | 5 | |
| PSA levels (ng/mL) | 29.4 (5.8; 115.7) | 20.4 (5.6; 94.3) | 121.4 (16.6; 567.8) | 0.09 |
| Missing | 34 | 0 | ||
| tALP (IU/L) | 84.5 (63.8; 168.2) | 86 (67; 167) | 90 (68.8; 292) | 0.1 |
| Missing | 74 | 7 | 0 | |
| Hb (g/L) | 130 (119; 143) | 132 (120.8; 143.2) | 122.5 (111.5; 134) | 0.14 |
| Missing | 77 | 0 | 0 | |
| White blood count (109/L) | 6.9 (5.5; 8.0) | 6.8 (5.5; 7.8) | 7.6 (5.8; 8.7) | 0.16 |
| Neutrophils (109/L) | 4.2 (3.4; 5.3) | 4.0 (3.2; 5) | 6.0 (4.6; 6.9) | 0.003 |
| Lymphocytes (109/L)) | 1.5 (1.1; 1.9) | 1.6 (1.3; 2) | 0.8 (0.7; 1) | <0.001 |
| NLR | 2.6 (2.1; 4.2) | 2.4 (1.9; 3) | 7.9 (5.6; 8; 7) | |
| Missing | 78 | 0 | 0 | |
| Platelets (109/L) | 227 (183.8; 264) | 230 (183; 261) | 200 (175.2; 270.8) | 0.29 |
| Missing | 78 | 0 | 0 | |
Eastern Cooperative Group (ECOG) performance status, prostate specific antigen (PSA) level, hemoglobin level (Hb), total alkaline phosphatase (tALP), and Neutrophil-to-lymphocyte ratio (NLR) was calculated as the ratio of the absolute neutrophil count (ANC) divided by the absolute lymphocyte count (ALC).